Sponsored Content | Case Study | Cardiovascular Business | December 13, 2016 | By Praveen Lobo, Vice President Strategic Products – LUMEDX Corporation

Improving the Business Performance of Heart and Vascular Centers

An effective data strategy facilitates improved business outcomes

cardiovascular data intelligence

New operational realities demand new ways of measuring the qualitative value of clinical procedures.


The primary goal of any healthcare provider is to improve the lives of patients through effective treatment. However, because they are also businesses, hospitals have concerns that entail much more than this. To be viable in the long term, hospitals must manage their margins to fund their mission.

There are three main pillars of business concern for any hospital:

  • Clinical — health outcomes are measured with the goal of healthier patients leaving the facility.
  • Financial — the dollars must add up to keep the enterprise solvent.
  • Operational — staffing and facilities are measured against cost and need.

Ultimate success for a hospital demands focused attention on all three areas. It's incumbent upon clinicians and service line managers to work together to seek out efficiencies in each of them. 

New Operational Realities

Payers' shift away from a fee-for-service model toward a value-based payment model demands that clinicians and administrators expand the above-mentioned pillars to include cost, patient outcomes, and patient satisfaction.

These changes aren’t easy. Providers have long been paid based on quantitative measures: the number of procedures performed. New operational realities demand new ways of measuring the qualitative value of those procedures. Reimbursement is linked to these metrics, and hospitals must find ways to leverage their investments in data technology in order to maximize their financial opportunities.

Granular Data Brings Actionable Insights

Data is critical to the shift to VBP. For example, for CABG procedures, if we know that extubation under 24 hours after surgery improves patient outcomes, it makes sense to monitor that metric internally on an ongoing basis. When outliers crop up, data points gathered from across the treatment spectrum can allow us to understand why. Perhaps a different treatment was needed at the outset, or some other patient health factor influenced that measure.

Over time, granular data can allow us to understand which type of treatment is best for patient outcomes in that circumstance.

It is discrete, granular data that can help providers fine-tune their processes in order to improve patient outcomes — and of course patient satisfaction. This same kind of close analysis can be applied to reducing costs. But for all three new, expanded pillars, efficient data collection, management, and analysis are needed. 

LUMEDX offers cardiovascular data intelligence: technologies that collect more than 30,000 discrete data points—from point-of-care devices to physician reporting. This rich data set enables meaningful insights in the areas of treatment options, clinical evaluation and training, and service line optimization.

Watch the VIDEO “Lumedx Cardiovascular Performance Program: A New Approach to Managing Quality and Cost.”

For more information, visit www.lumedx.com


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now